article
21 March 2019 | By Massimiliano Runfola - University of Pisa - Italy, Sheraz Gul - Fraunhofer IME - Germany
Over the past 30 years, one strategy the pharmaceutical industry has adopted in the drug discovery process has been to “fail early, fail often”.1,2 As most molecules in the early stages of drug discovery will have sub-optimal characteristics, significant modification is necessary to improve their properties.